Agios Pharmaceuticals, Inc. (AGIO) stock analysis

In our weekly check, Agios Pharmaceuticals, Inc. is graded D (A to F). Of 21 checks on debt, profit, cash flow and trend: 9 pass, warnings: 3, red flags: 9.

About Agios Pharmaceuticals, Inc.

Agios Pharmaceuticals, Inc. is a Healthcare company (Biotechnology) based in the United States, listed on NASDAQ as AGIO.

What our checks show for AGIO

Red flags

Warning signs

Strengths

Next earnings report: 2027-02-11

Similar companies

ZBIO · MAZE · FTRE · TRVI · ZYME

Questions

What grade does Agios Pharmaceuticals, Inc. (AGIO) have?

In our weekly check, Agios Pharmaceuticals, Inc. is graded D (A to F). Of 21 checks on debt, profit, cash flow and trend: 9 pass, warnings: 3, red flags: 9. The grade is a risk check, not a buy or sell recommendation.

What are the main risks of AGIO stock?

This week's biggest flags for Agios Pharmaceuticals, Inc.: Margins falling, Weak EPS forecast, Weak EPS growth. In total 12 of 21 checks show a warning or a red flag.

What does Agios Pharmaceuticals, Inc. do?

Agios Pharmaceuticals, Inc. is a Healthcare company (Biotechnology) based in the United States, listed on NASDAQ as AGIO.

When does Agios Pharmaceuticals, Inc. report earnings next?

The next earnings report is expected on 2027-02-11. We re-run the checks every week, so the grade can change after it.

The grade is a risk check, not a price forecast, and not investment advice. In our 10-year test (S&P 500, 2016-2026), stocks we graded A or B fell more than 30% 2-3 times less often than D or F, without a lower average return.

Updated 2026-11-14

Open the full analysis